Daporinad

N/A

Report date: 2022/11/25 17:25:13
NME

Base Information

Drug NameDaporinad
Drug Alias Namedaporinadum达泊利那达珀利那NMPRTsFK-866 +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionNicotinamide phosphoribosyltransferase inhibitors
TargetsNicotinamide phosphoribosyltransferase
Therapy Area/IndicationsMelanomaLymphoma, T-Cell, CutaneousLeukemia, Lymphocytic, Chronic, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustriaGermanySwitzerland +[5] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesValerio Therapeutics SA
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesTopotarget ASValerio Therapeutics SA
Active IndicationsN/A
Inactive IndicationsMelanomaLymphoma, T-Cell, CutaneousLeukemia, Lymphocytic, Chronic, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A